Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL C UBA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578540860
CMS profile
206711
Location
FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,791.32

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,925.55 190
Travel and Lodging $1,865.77 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–193 of 193 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL C UBA

NPI 1578540860 · CMS profile ID 206711

Allopathic & Osteopathic Physicians / Internal Medicine

FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–193 of 193 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–193 of 193 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–193 of 193 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–193 of 193 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $4,791.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–193 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $19.5703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171641 CMS
GlaxoSmithKline, LLC. $4.4803/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681843 CMS
GlaxoSmithKline, LLC. $13.9903/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682243 CMS
AstraZeneca Pharmaceuticals LP $14.9603/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015208037 CMS
ITI, Inc. $25.2303/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040727461 CMS
Novo Nordisk Inc $15.4103/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171459 CMS
GlaxoSmithKline, LLC. $12.5003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681525 CMS
Medtronic, Inc. $3.8503/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003117 CMS
Lilly USA, LLC $17.4802/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031359125 CMS
AstraZeneca Pharmaceuticals LP $15.1302/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011349687 CMS
AstraZeneca Pharmaceuticals LP $48.4202/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011801731 CMS
GlaxoSmithKline, LLC. $2.7302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682291 CMS
Novo Nordisk Inc $16.5902/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171515 CMS
GlaxoSmithKline, LLC. $15.0502/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681893 CMS
AstraZeneca Pharmaceuticals LP $17.1702/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011604209 CMS
Exact Sciences Corporation $24.0902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026510235 CMS
Novo Nordisk Inc $15.4102/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171445 CMS
Medtronic, Inc. $4.2202/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003109 CMS
ITI, Inc. $26.4302/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040727453 CMS
Novartis Pharmaceuticals Corporation $14.4202/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993402925 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $22.7202/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057323607 CMS
GlaxoSmithKline, LLC. $18.3502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681817 CMS
Novo Nordisk Inc $15.3302/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171434 CMS
GlaxoSmithKline, LLC. $6.1002/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681873 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.9502/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000282309 CMS
Novo Nordisk Inc $14.3602/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171411 CMS
GlaxoSmithKline, LLC. $11.1901/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682359 CMS
GlaxoSmithKline, LLC. $4.5501/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682577 CMS
AstraZeneca Pharmaceuticals LP $16.2501/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011312929 CMS
GlaxoSmithKline, LLC. $6.1001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681505 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.3201/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000262249 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.9801/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996990191 CMS
Ironwood Pharmaceuticals, Inc $14.7101/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045571101 CMS
GlaxoSmithKline, LLC. $1.6501/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681835 CMS
Lilly USA, LLC $17.2201/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031433157 CMS
Amgen Inc. $12.9901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020559603 CMS
Novo Nordisk Inc $13.9601/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171387 CMS
Novo Nordisk Inc $14.1101/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171399 CMS
AstraZeneca Pharmaceuticals LP $13.4401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011614617 CMS
Merck Sharp & Dohme LLC $23.4501/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048263509 CMS
Medtronic, Inc. $7.7201/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003093 CMS
Novo Nordisk Inc $13.8601/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171375 CMS
Medtronic, Inc. $3.6401/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003101 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,677.51 219
PY2020 $1,953.22 139
PY2021 $2,950.48 205
PY2022 $2,953.01 168
PY2023 $4,791.32 193
PY2024 $3,045.02 117
PY2025 $2,072.54 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $678,672.13 11
PY2024 Recipient $99,780.00 1
PY2024 Principal investigator $372,920.00 13
PY2023 Principal investigator $18,987.84 5
PY2022 Principal investigator $7,788.32 4
PY2021 Principal investigator $2,970.75 7
PY2020 Principal investigator $7,452.25 7
PY2019 Principal investigator $55,394.72 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $870.52 09/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187878569
Principal investigator 1 Eli Lilly and Company $170,084.00 08/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187876515
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878383
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $4,545.23 04/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187877205
Principal investigator 1 Eli Lilly and Company $339.50 03/26/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880543
Principal investigator 1 Eli Lilly and Company $8,432.94 02/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876747
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187890980
Principal investigator 1 Eli Lilly and Company $10,324.96 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877277
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,749.99 01/15/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185541048
Principal investigator 1 Eli Lilly and Company $49,590.99 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878357
Principal investigator 1 Eli Lilly and Company $415,164.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882742